Previous 10 | Next 10 |
2024-04-23 10:29:06 ET More on Edgewise Therapeutics Edgewise Therapeutics: Behind The Massive Rally Krystal Biotech, Candel, Edgewise gain after FDA fast track tags Seeking Alpha’s Quant Rating on Edgewise Therapeutics Historical earnings data for Edg...
2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...
2024-04-22 12:53:43 ET More on S&P 500 Index: Fed's Commercial Banking Report Shows Economic Headwinds, But Deposit Growth Bucks Trend S&P 500: Capitulation? Week Starting 22nd April (Technical Analysis) Powell Playing Games: 'Sell In May' Is Now 'Sell Before...
2024-04-22 12:03:46 ET More on GSK, Sanofi, etc. GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) GSK shingles vaccine shown 82% ...
2024-04-22 11:04:15 ET More on S&P 500 Index: Fed's Commercial Banking Report Shows Economic Headwinds, But Deposit Growth Bucks Trend S&P 500: Capitulation? Week Starting 22nd April (Technical Analysis) Powell Playing Games: 'Sell In May' Is Now 'Sell Before...
2024-04-22 10:14:17 ET More on AbbVie, Pfizer, etc. Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie suc...
EMBLAVEO ® is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by multidrug-resistant Gram-negative bacteria, including metallo-β-lactamase-producing bacteria ...
2024-04-22 08:00:00 ET Summary 2023 was up 24%. 3 months down in 2024 and the S&P 500 is already up 6%, down from the plus 10% they were at. We are missing a few hundred in dividend income in March of this year, we normally would have had, but will be added to the April divide...
2024-04-21 20:04:07 ET More on Eli Lilly, Novo Nordisk, etc. Read the full article on Seeking Alpha For further details see: 13 new obesity drugs could hit the market by 2029 amid surging demand
2024-04-21 14:42:04 ET More on the markets SPY: Higher For Longer Could Be Good News S&P 500: Positive Outlook, I'm Modifying My Hedge SPY: Resurgent Inflation, Soaring Yields, Geopolitical Turmoil - 1970s All Over Again? Wall Street's April pullback inte...
News, Short Squeeze, Breakout and More Instantly...
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA)...
2024-05-17 21:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...